An authoritative guide to Leber's Hereditary Optic Neuropathy — real answers, verified supplements, and the research decoded by someone living it.
LHON is a mitochondrial genetic condition — not a death sentence for your quality of life. Understanding the biology is the first step to making informed decisions.
Read LHON 101 →The three primary mutations (11778, 3460, 14484) each carry different prognosis profiles and spontaneous recovery rates. Knowing yours changes what you should prioritize.
Learn about mutations →Most ophthalmologists are not equipped to manage LHON. You need a neuro-ophthalmologist who has seen LHON patients. This is the most important call you'll make.
How to find one →Not a textbook definition. A real explanation of what's happening in your body — written by someone who has lived it and studied it for decades.
A mitochondrial genetic disease that causes sudden, severe, painless loss of central vision due to optic nerve degeneration.
Read more →11778, 3460, and 14484 are not the same. Each has a different prognosis, recovery rate, and response to treatment.
Compare mutations →It happens. The 14484 mutation has the highest rate. Understand the realistic odds and what can influence your window.
Recovery explained →LHON is maternally inherited but disproportionately affects males. The biology behind this — and what it means for carriers.
Genetics explained →Peripheral neuropathy, tremors, cardiac issues, migraine. The non-vision symptoms that aren't always discussed at diagnosis.
LHON Plus →Smoking is one of the strongest environmental triggers for LHON. For carriers, it significantly raises the risk of conversion. Certain medications are also known triggers. The full list.
Risk factors →Not press releases. A real-time breakdown of what the clinical research says — decoded for patients.
The FDA issued a Complete Response Letter to Chiesi in March 2026. No new safety concerns — but more clinical data required. Here's what it means for US patients and what to do right now.
Read the full breakdown →The only disease-specific treatment — approved in EU/UK, rejected in US. What the LEROS trial showed, the correct clinical dose, and the quality sourcing problem.
Idebenone deep dive →Intravitreal gene therapy for the 11778 mutation has produced real results in trials. Not yet accessible in the US — but the science is advancing.
Gene therapy update →Clinical research translated into plain language — by someone who has a personal stake in getting it right.
The FDA issued a Complete Response Letter to Chiesi in March 2026. Here's the plain-language breakdown of what happened and the practical steps for patients.
Read more → 8 minBeyond idebenone — the full supplement protocol built around 20 years of research and lived experience with LHON.
A patient-facing breakdown of the gene therapy landscape — what the trials showed, who qualifies, and how to ask your doctor.
The LHON community is global, resilient, and actively pushing for better research and treatment access.